Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor.
John Daly , Subhashis Sarkar , Alessandro Natoni , Robert Henderson
Clinical Lymphoma, Myeloma & Leukemia 19 ( 10)
2019
G2/M Arrest Sensitizes Chronic Myelogenous Leukemia Cells to TRAIL-Induced Apoptosis
David Devlin , Eva Szegezdi , Paavilainen Tanja , Orsolya Orosz
Blood 116 ( 21) 4465 -4465
2010
Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR
Eibhlin Conneally , Ronan T Swords , Francis J. Giles , Mary Frances McMullin
Blood 116 ( 21) 3427 -3427
6
2010
Interferon-γ–induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8–dependent activation of caspase 3 family members
R. Keaney Rathbun , Tracy A. Christianson , Gregory R. Faulkner , Gary Jones
Blood 96 ( 13) 4204 -4211
78
2000
Role of double-stranded RNA-dependent protein kinase in mediating hypersensitivity of Fanconi anemia complementation group C cells to interferon γ, tumor necrosis factor-α, and double-stranded RNA
Qishen Pang , Winifred Keeble , Jane Diaz , Tracy A. Christianson
Blood 97 ( 6) 1644 -1652
61
2001
Cutaneous hypereosinophilia secondary to a low-grade B-cell lymphoma.
Niamh Byrne , Annette Murphy , Michael O'Dwyer
International Journal of Dermatology 58 ( 8)
2019
Home administration of bortezomib: making a difference to myeloma patients' lives.
Teresa Meenaghan , Michael O'Dwyer , Patrick Hayden , Amjad Hayat
European Journal of Oncology Nursing 14 ( 2) 134 -136
6
2010
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
Daniel J. DeAngelo , Harry Paul Erba , Brian Andrew Jonas , Michael O'Dwyer
Journal of Clinical Oncology 37 ( 15)
7
2019
Multifaceted approach to the treatment of bcr-abl-positive leukemias.
Michael O'Dwyer
Oncologist 7 ( 90001) 30 -38
29
2002
STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
Michael Mauro , Michael O'Dwyer , Brian Druker
Cancer Chemotherapy and Pharmacology 48 ( 1)
33
2001
Perifosine--a new option in treatment of acute myeloid leukemia?
Janusz Krawczyk , Niamh Keane , Ronan Swords , Michael O'Dwyer
Expert Opinion on Investigational Drugs 22 ( 10) 1315 -1327
10
2013
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Steven Coutre , John C. Byrd , Peter Hillmen , Jacqueline C. Barrientos
Blood 128 ( 22) 4383 -4383
6
2016
5-Azacytidine for the treatment of myelodysplastic syndromes.
Janusz Krawczyk , Niamh Keane , Ciara Louise Freeman , Ronan Swords
Expert Opinion on Pharmacotherapy 14 ( 9) 1255 -1268
10
2013
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Ronan T. Swords , Kevin R. Kelly , Peter G. Smith , James J. Garnsey
Blood 115 ( 18) 3796 -3800
273
2010
Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.
Joanne O'Dwyer , Roisin E. O'Cearbhaill , Robert Wylie , Saoirse O'Mahony
Advanced Therapeutics 3 ( 11) 2000144
2020
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry Facon , Shaji K Kumar , Torben Plesner , Robert Z Orlowski
The Lancet Oncology 22 ( 11) 1582 -1596
70
2021
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Yi Lin , Lugui Qiu , Saad Usmani , Chng Wee Joo
The Lancet Oncology
2024
Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia study
Shaji K Kumar , Philippe Moreau , Nizar Jacques Bahlis , Thierry Facon
Blood 140 ( Supplement 1) 10150 -10153
21
2022
Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the Phase 3 Maia Study
Philippe Moreau , Thierry Facon , Saad Usmani , Nizar Jacques Bahlis
Blood 140 ( Supplement 1) 7297 -7300
15
2022
Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: maia age subgroup analysis
Thierry Facon , Shaji K Kumar , Katja Weisel , Saad Usmani
Blood 140 ( Supplement 1) 10133 -10136
9
2022